The Democratic Party won majorities in both chambers in the 3 November US midterm elections, drawing attention to the future direction of President Trump's MFN pricing and pharmaceutical tariff policies.
The Democratic Party's victory in both chambers could lead to changes in the Trump administration's pressure to reduce MFN prices and its policy of promoting pharmaceutical tariffs. Congressional scrutiny of the means of implementation, scope and speed of the policies is expected to intensify.
Developments concerning GLOBE and GUARD will remain closely watched. Final rules for GLOBE have been published, with implementation expected to begin in 2027. GUARD's final rules have not been published, and its start date remains unclear, with the possibility of a delay and the program potentially being affected by developments in Congress.
The administration may continue to pursue a policy of flexibly applying exemptions and preferential treatment for tariffs depending on the conditions of investment in domestic US manufacturing and drug-pricing agreements, while maintaining the current framework. Adjustments to the operation of the existing system are more likely to be central than its complete abolition.
Japanese companies need to consider MFN agreements, the conditions for tariff preferences, trends in investment in domestic US manufacturing, and pricing in Japan and Europe as a whole. Many observers believe it is not yet time to revise business plans on the assumption that the election results will bring about an easing of policy.